Publication | Open Access

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

Surgical OncologyMedicineStandard TreatmentNon-randomised Phase 2Cancer TreatmentOncologyRadiation OncologyOrthopaedic SurgeryCancer Research